

1652
I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date of Signature and Deposit: October 9, 2000


Nicholas J. Seay

RECEIVED

OCT 17 2000

PATENT TECH CENTER 1600/2800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ronald T. Raines

Serial No.: 09/234,028

Filed: 01/20/99

Title: OXIDATION-RESISTANT
RIBONUCLEASE INHIBITOR



Date: October 9, 2000

Group Art Unit: 1652

Examiner: R. Hutson

File No.: 960296.95360

#8
P.S.
10/19/00

RESPONSE TO REQUIREMENT FOR RESTRICTION

Commissioner For Patents
Washington DC 20231

Dear Sir:


In response to an office action dated September 28, 2000 in the file of the above-identified application, which imposed a requirement for restriction on the applicant, the applicant responds herewith as follows:

The applicant hereby elects the inventions of Group I, Claims 1-10, drawn to a mutant ribonuclease inhibitor. This election is made with traverse.

The requirement for restriction is traversed because the subject matter of Groups I and II are inextricably linked. A proper search for the subject matter of Claims 1-10 will inevitably include the DNA sequence which are recited and claimed in Claims 11-14. As such, it will be unnecessarily burdensome on both the applicant and the Office to consider this highly related subject matter in two separate patent applications. For these reasons it is requested that the restriction requirement be reconsidered and withdrawn.

Wherefore examination on the merits is respectfully requested.

Respectfully submitted,


Nicholas J. Seay
Reg. No. 27,386
Attorney for Applicant
QUARLES & BRADY LLP
P O Box 2113
Madison, WI 53701-2113

TEL 608/251-5000
FAX 608/251-9166